| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV-PHARMTOX-010715-103143 |
| P698 | PubMed publication ID | 26514207 |
| P50 | author | George Koob | Q5541413 |
| P2093 | author name string | Barbara J Mason | |
| P2860 | cites work | Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor | Q24311708 |
| P304 | page(s) | 299-322 | |
| P577 | publication date | 2015-10-22 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Existing and Future Drugs for the Treatment of the Dark Side of Addiction | |
| P478 | volume | 56 |
| Q45068179 | 21st century neurobehavioral theories of decision making in addiction: Review and evaluation. |
| Q30275691 | A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence |
| Q48305376 | AMPA Receptor Plasticity in the Nucleus Accumbens Mediates Withdrawal-Related Negative-Affective States. |
| Q38801049 | An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism. |
| Q56505162 | Cannabis Addiction and the Brain: a Review |
| Q64230853 | Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation |
| Q39470202 | Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs. |
| Q58587374 | Determinants of Opioid Abuse Potential:Insights Using Intracranial Self-Stimulation |
| Q47302967 | Different functional domains measured by cocaine self-administration under the progressive-ratio and punishment schedules in male Wistar rats |
| Q37059221 | Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development |
| Q93013726 | Dopamine D3 Receptor Antagonism Reverses the Escalation of Oxycodone Self-administration and Decreases Withdrawal-Induced Hyperalgesia and Irritability-Like Behavior in Oxycodone-Dependent Heterogeneous Stock Rats |
| Q90568986 | Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects |
| Q39365977 | Dysregulation of Brain Stress Systems Mediates Compulsive Alcohol Drinking |
| Q37137786 | Effects of Trace Amine-associated Receptor 1 Agonists on the Expression, Reconsolidation, and Extinction of Cocaine Reward Memory |
| Q38689594 | Emerging pharmacotherapies for alcohol use disorder |
| Q39125044 | Epigenetic basis of the dark side of alcohol addiction |
| Q87681753 | Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment |
| Q47910117 | Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice. |
| Q39028819 | Insights from Preclinical Choice Models on Treating Drug Addiction |
| Q52317998 | Involvement of activated brain stress responsive systems in excessive and "relapse" alcohol drinking in rodent models: implications for therapeutics. |
| Q61811943 | Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression |
| Q38669858 | Modeling the development of drug addiction in male and female animals |
| Q39262233 | Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development |
| Q34535855 | Neurobiology of addiction: a neurocircuitry analysis |
| Q88396582 | Neuroclinical Framework for the Role of Stress in Addiction |
| Q51438275 | Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development. |
| Q92145824 | Nuclear transcriptional changes in hypothalamus of Pomc enhancer knockout mice after excessive alcohol drinking |
| Q89207660 | Opioid receptors: drivers to addiction? |
| Q47572906 | Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes |
| Q92720740 | Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers |
| Q48305886 | The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? |
| Q46092660 | The central extended amygdala in fear and anxiety: Closing the gap between mechanistic and neuroimaging research |
| Q90175435 | The multifaceted potential of the lipid transmitter oleoylethanolamide to treat alcohol-induced neuroinflammation and alcohol use disorders |
Search more.